Leukaemia Trial, Recruiting (NCT06956755)

Leukaemia Trial, Recruiting NCT06956755 Sponsor: Groupe Francophone des Myelodysplasies Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06956755 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People of any gender are eligible.
People who are over 18 years old are eligible.
People who have been diagnosed with myelodysplastic syndrome (a condition where the bone marrow does not produce enough healthy blood cells) or therapy-related acute myeloid leukemia (a type of blood cancer that develops as a result of previous cancer treatment) are eligible.
People who are able and willing to sign a written consent form agreeing to take part are eligible.

Who may not be able to join:

People who are under 18 years old would not be eligible.
People who are unwilling or unable to provide consent to participate would not be eligible.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33(0)1 71 20 70 59

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06956755

Sponsor: Groupe Francophone des Myelodysplasies

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: +33(0)1 71 20 70 59

More information: https://clinicaltrials.gov/study/NCT06956755

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People of any gender are eligible.
People who are over 18 years old are eligible.
People who have been diagnosed with myelodysplastic syndrome (a condition where the bone marrow does not produce enough healthy blood cells) or therapy-related acute myeloid leukemia (a type of blood cancer that develops as a result of previous cancer treatment) are eligible.
People who are able and willing to sign a written consent form agreeing to take part are eligible.

Who may not be able to join:

People who are under 18 years old would not be eligible.
People who are unwilling or unable to provide consent to participate would not be eligible.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Groupe Francophone des Myelodysplasies

Registry

ClinicalTrials.gov

Start date

7 July 2003

Est. completion

5 January 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Hemoglobin level Unit of Measure g/dL; Absolute neutrophil count / Unit of Measure G/L; Platelet count Unit of Measure / Unit of Measure: %G/L; Percentage of bone marrow blasts at enrollment / Unit of Measure: percent; Presence of multilineage dysplasia at enrollment / Unit of Measure percent of patients; Cytogenetic abnormalities at enrollment / Unit of Measure percent of patients; IPSS-R risk classification at enrollment / Unit of Measure percent of patients by category; Presence of somatic mutations at enrollment / Unit of Measure: percent of patients; Demographic characteristics at enrollm...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov